Elevation Oncology, Inc.

NasdaqGS:ELEV Stock Report

Market Cap: US$36.0m

Elevation Oncology Past Earnings Performance

Past criteria checks 0/6

Elevation Oncology's earnings have been declining at an average annual rate of -20.9%, while the Biotechs industry saw earnings growing at 19.3% annually.

Key information

-20.9%

Earnings growth rate

64.7%

EPS growth rate

Biotechs Industry Growth17.0%
Revenue growth raten/a
Return on equity-60.5%
Net Marginn/a
Last Earnings Update30 Sep 2024

Recent past performance updates

No updates

Recent updates

Elevation Oncology: Mid-2024 EO-3021 Data Could Get Ball Rolling

May 03

Elevation Oncology: Rising On News, But Not The Time To Buy

Jan 17

Elevation Oncology GAAP EPS of -$0.86 misses by $0.07

Aug 04

Elevation Oncology secured $50M loan facility with K2 HealthVentures

Jul 28

We're Hopeful That Elevation Oncology (NASDAQ:ELEV) Will Use Its Cash Wisely

May 10
We're Hopeful That Elevation Oncology (NASDAQ:ELEV) Will Use Its Cash Wisely

We're Not Very Worried About Elevation Oncology's (NASDAQ:ELEV) Cash Burn Rate

Jan 25
We're Not Very Worried About Elevation Oncology's (NASDAQ:ELEV) Cash Burn Rate

Companies Like Elevation Oncology (NASDAQ:ELEV) Are In A Position To Invest In Growth

Sep 25
Companies Like Elevation Oncology (NASDAQ:ELEV) Are In A Position To Invest In Growth

Revenue & Expenses Breakdown

How Elevation Oncology makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

NasdaqGS:ELEV Revenue, expenses and earnings (USD Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Sep 240-421527
30 Jun 240-401525
31 Mar 240-391424
31 Dec 230-461525
30 Sep 230-571635
30 Jun 230-851662
31 Mar 230-951672
31 Dec 220-951679
30 Sep 220-861570
30 Jun 220-591445
31 Mar 220-441133
31 Dec 210-32824
30 Sep 210-31626
30 Jun 210-22319
31 Mar 210-20218
31 Dec 200-17215

Quality Earnings: ELEV is currently unprofitable.

Growing Profit Margin: ELEV is currently unprofitable.


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: ELEV is unprofitable, and losses have increased over the past 5 years at a rate of 20.9% per year.

Accelerating Growth: Unable to compare ELEV's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: ELEV is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (16.6%).


Return on Equity

High ROE: ELEV has a negative Return on Equity (-60.48%), as it is currently unprofitable.


Return on Assets


Return on Capital Employed


Discover strong past performing companies